Inactive Instrument

ArQule, Inc.

Equities

US04269E1073

Biotechnology & Medical Research

ArQule, Inc. Provides Earnings Guidance for the Full Year 2019

March 07, 2019 at 05:30 pm IST

ArQule, Inc. provided earnings guidance for the full year 2019. For 2019, the company expected revenue to be in the range of $3 and $5 million. Net loss is expected to be in the range of $40 and $43 million, and net loss per share to range between $0.37 and $0.39 for the year.

Latest news about ArQule, Inc.

ArQule, Inc. Announces Management Changes	16/20/16	CI
ArQule, Inc.(NasdaqGM:ARQL) dropped from S&P TMI Index	16/20/16	CI
ArQule, Inc.(NasdaqGM:ARQL) dropped from S&P Biotechnology Select Industry Index	16/20/16	CI
ArQule, Inc.(NasdaqGM:ARQL) dropped from S&P Global BMI Index	16/20/16	CI
Merck Sharp & Dohme Corp. completed the acquisition of ArQule, Inc..	15/20/15	CI
Wall St. falls as Apple, health shares drag, tariff deadline looms	10/19/10	RE
Transcript : ArQule, Inc. - Special Call	09/19/09
ArQule, Inc. Announces Final Phase 1 Clinical Data for Its Reversible BTK Inhibitor, ARQ 531, at the American Society of Hematology 2019 Annual Meeting	09/19/09	CI
Merck Sharp & Dohme Corp. entered into a definitive agreement to acquire ArQule, Inc. for $2.4 billion.	09/19/09	CI
ArQule to Present Clinical Data for its Reversible BTK Inhibitor, ARQ 531, at the American Society of Hematology 2019 Annual Meeting	25/19/25	CI
ArQule, Inc. Announces Release of American Society of Hematology Abstract Detailing Results of the Ongoing Phase 1 Study of Reversible BTK Inhibitor, ARQ 531, in Patients with Relapsed/Refractory Hematologic Malignancies	06/19/06	CI
Transcript : ArQule, Inc., Q3 2019 Earnings Call, Oct 30, 2019	30/19/30
ArQule, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019	30/19/30	CI
ArQule, Inc. Provides Financial Guidance for 2019	30/19/30	CI
ArQule, Inc. Presents Recent Data on ARQ 751	30/19/30	CI
ArQule Announces Preclinical Data Demonstrating Potential of Miransertib (ARQ 092) to Treat PIK3CA-Driven Vascular Malformations at 2019 ASHG Annual Meeting	21/19/21	CI
ArQule Announces Presentations on ARQ 751 at the 2019 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics	16/19/16	CI
ArQule, Inc. Announces First Patient Dosed in Registrational MOSIAC Trial of Miransertib for the Treatment of Proteus Syndrome and PIK3CA-related Overgrowth Spectrum	02/19/02	CI
Certain Common Stock of ArQule, Inc. are subject to a Lock-Up Agreement Ending on 23-SEP-2019.	23/19/23	CI
Certain Warrants of ArQule, Inc. are subject to a Lock-Up Agreement Ending on 23-SEP-2019.	23/19/23	CI
Certain Options of ArQule, Inc. are subject to a Lock-Up Agreement Ending on 23-SEP-2019.	23/19/23	CI
Transcript : ArQule, Inc. Presents at Citi's 14th Annual Biotech Conference, Sep-04-2019 03:00 PM	05/19/05
Transcript : ArQule, Inc., Q2 2019 Earnings Call, Aug 07, 2019	07/19/07
ArQule, Inc. Provides Financial Guidance for the Fiscal Year 2019	07/19/07	CI
Arqule, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2019	07/19/07	CI

Chart ArQule, Inc.

Duration

Period

More charts

Company Profile

ArQule, Inc. is a biopharmaceutical company that is engaged in the research and development of therapeutics to treat cancers and rare diseases. These drugs focus on the biological pathways implicated in a range of cancers and certain non-oncology indications. Its clinical-stage pipeline consists of approximately four drug candidates, all of which are in targeted patient populations. The Company's product candidates include ARQ 531, Miransertib (ARQ 092), ARQ 751, Miransertib (ARQ 092) and ARQ 751. ARQ 531 is a potent and reversible dual inhibitor of both wild type and C481S-mutant Bruton's tyrosine kinase (BTK). ARQ 092 is a potent and selective inhibitor of protein kinase B (AKT), a serine/threonine kinase. ARQ 751 is a potent and selective inhibitor of AKT that is in Phase I clinical development for solid tumors harboring AKT, phosphoinositide 3-kinase (PI3K). ARQ 087 is a multi-kinase inhibitor designed to preferentially inhibit the fibroblast.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+33.63%	5.08TCr
IQVIA HOLDINGS INC.	-0.09%	4.28TCr
LONZA GROUP AG	+49.62%	4.2TCr
CELLTRION, INC.	-4.96%	2.95TCr
ICON PUBLIC LIMITED COMPANY	+11.18%	2.61TCr
ALNYLAM PHARMACEUTICALS, INC.	-21.95%	1.91TCr
BIO-TECHNE CORPORATION	+8.61%	1.31TCr
MEDPACE HOLDINGS, INC.	+28.31%	1.22TCr
UNITED THERAPEUTICS CORPORATION	+24.73%	1.21TCr

Other Biotechnology & Medical Research